← All trials
NCT00591058
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 1, 2008
- Primary completion
- Feb 1, 2010
- Completion date
- Feb 1, 2010
- First posted
- —
- Last posted
- —
- Enrollment
- 36
- Arms / groups
- 6 / —
- Source
- AACT · pre-existing
Sponsors
- TransMolecularLead sponsor
- Wake Forest UniversityOverall official - principal investigator
- Columbia UniversityOverall official - principal investigator
- Northwestern UniversityOverall official - principal investigator
- Cedars-Sinai Medical CenterOverall official - principal investigator
- University of WashingtonOverall official - principal investigator
- Washington University in St. LouisOverall official - principal investigator
- University of Alabama, BirminghamOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.